E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary Hypertension ``out-of-proportion`` associated to moderate left ventricular dysfunction |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037406 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
TO EVALUATE THE HEMODYNAMIC EFFECT OF 6 MONTHS TADALAFIL ADMINISTRATION ON THE IMPROVEMENT OF PULMONARY VASCULAR RESISTANCE (pvr) ESTIMATION BY RIGHT HEART CATHETERIZATION IN OUT-OF-PROPORTION PULMONARY HYPERTENSION (PH) ASSOCIATED TO MODERATE LEFT VENTRICULAR DYSFUNCTION (A SUB-GROUP OF THE 2� CATEGORY OF THE WHO CLINICAL CLASSIFICATION SYSTEM-VENICE 2003 REVISION) |
|
E.2.2 | Secondary objectives of the trial |
- evaluation of the effect of 6 months treatment with tadalafil on the right heart remodelling, measuring the changes in Ventricular Mass (VM), Ventricular Volume (VV), VM/VV ratio, Ejection Fraction (EF), intraventricular asynchrony by MRI; - evaluation of the effect of 6 months treatment with Tadalafil on hemodynamic parameters: Cardiac Index (L/min/m2) and mean right atrial pressure (RAPm), mean pulmonary arterial pressure (PAPm), Pulmonary wedge Pressure (PWP), mean aortic pressure (PAom) by catheterization; - improvement in effort capacity: 6-Minutes Walking Test (6MWT) - to assess the changes in endothelial function parameters: endothelin 1, sCRP, cGMP, atrial and brain natriuretic peptide (ANP - BNP) and cytokines (IL1, IL6, TGF beta, TNF alfa, VEGF, VCAM) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
patients aged > 18 yrs with out-of-proportion hypertension associated to moderate left ventricular dysfunction (a subgroup of the 2� category of the WHO clinical classification system Venice 2003 ervision) NYHA class IIa referred to pulmonary hypertension center for evaluation. - moderate left ventricular dysfunction is defined as left ventricular ejection fraction between 35 and 45% - pulmonary hypertension out-of-proportion associated to left ventricular dysfunction is defined as mean mean pulmonary arterial pressure (PAP ≥ 40-45 mmHg and a transpulmonary pressure gradient (mean PAP- mean pulmonary wedge pressure –PWP) > 12 mmHg (ESC-ERS Guidelines 2009) |
|
E.4 | Principal exclusion criteria |
Exclusion criteria will be idiopatic pulmonary hypertension and pulmonary hypertension secondary to chronic obstructive or restrictive pulmonary disease, recurrent pulmonary embolism, pulmonary venous congestion, acute or chronic inflammatory lung disease, pregnancy or insufficient contraceptive measures, and previous treatment with PDE inhibitors and contraindication to assumption of PDE5i (patients with hepatic or renal insufficiency and known retinal disease) and concomitant use of nitrate. Hypersensitivity to the active substance or to any of the excipients. Acute myocardial infarction within the last 90 days. Severe hypotension (<90/50 mm Hg). Patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure. Patients with clinically significant aortic and mitral valve disease. Patients with pericardial constriction. Patients with restrictive or congestive cardiomyopathy . Patients with significant left ventricular dysfunction. Patients with life-threatening arrhythmias. Patients with symptomatic coronary artery disease . Patients with uncontrolled hypertension. Pulmonary veno-occlusive disease (PVOD). Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied and therefore dosing. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Objective: to evaluate the hemodynamic effect of 6 months Tadalafil administration on the improvement of Pulmonary Vascular Resistance (PVR) estimation by right heart Catheterization. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
validare una metodica diagnostica meno invasiva |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |